Biogen and denali therapeutics announce initiation of the phase 3 lighthouse study in parkinson's disease associated with lrrk2 pathogenic mutations

Cambridge, mass. and south san francisco, calif., oct. 03, 2022 (globe newswire) -- biogen inc. (nasdaq: biib) and denali therapeutics inc. (nasdaq: dnli) today announced that dosing has commenced in the global phase 3 lighthouse study to evaluate the efficacy and safety profile of biib122 (dnl151), as compared to placebo in approximately 400 participants with parkinson's disease and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (lrrk2) gene.
DNLI Ratings Summary
DNLI Quant Ranking